The Rho-kinase pathway regulates angiotensin II-induced renal damage  by Rupérez, Mónica et al.
Kidney International, Vol. 68, Supplement 99 (2005), pp. S39–S45
III. PROGRESSION OF CKD
The Rho-kinase pathway regulates angiotensin II-induced renal
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The Rho-kinase pathway regulates angiotensin II-induced renal
damage.
Background. Angiotensin II (AngII) is a key factor in the
pathogenesis of renal damage. AngII via AngII type 1 recep-
tors activates several intracellular signaling systems, including
the small guanosine triphosphatase Rho and its downstream
effector Rho-dependent serine-threonine kinase (Rho-kinase).
The Rho/Rho-kinase pathway contributes to inflammatory and
proliferative changes observed in cardiovascular diseases. How-
ever, the data on renal diseases are scarce. The aim of this study
was to investigate the effect of Rho-kinase inhibition in AngII-
induced renal damage.
Methods. We used the model of systemic AngII infusion
into normal rats (100 ng/kg per minute; subcutaneous osmotic
minipumps), and some animals were treated with the Rho-
kinase inhibitor Y-27632 (30 mg/kg per day). In the kidneys of
these animals, we evaluated renal lesions, transcription factor
activity (by electrophoretic mobility shift assay), and messen-
ger RNA (by polymerase chain reaction) and protein expres-
sion levels (by Western blot and/or immunohistochemistry) of
proinflammatory and profibrotic factors.
Results. Rats infused with AngII for three days present renal
inflammatory cell infiltration and slight tubular damage, which
were diminished by treatment with the Rho-kinase inhibitor
Y-27632. AngII activates nuclear factor-jB and causes overex-
pression of proinflammatory factors, including cytokines (tu-
mor necrosis factor a) and chemokines (monocyte chemotactic
protein-1), and of profibrotic factors (connective tissue growth
factor). Treatment of AngII-infused rats with Y-27632 decreases
the upregulation of these proinflammatory and profibrotic me-
diators.
Conclusion. These data demonstrate that the Rho-kinase
pathway is involved in renal damage caused by AngII through
the regulation of proinflammatory and profibrotic mediators.
These results suggest that inhibition of the Rho-kinase path-
way represents a novel therapy for renal diseases associated
with local AngII generation.
Angiotensin II (AngII), the main peptide of the
renin-angiotensin system, has been implicated in the
pathogenesis of renal diseases [1, 2]. Renin-angiotensin
system blockers are commonly used in the treatment of
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hypertension and proteinuria in humans [3]. In exper-
imental models of renal injury, pharmacologic block-
ade of AngII actions, by angiotensin-converting enzyme
(ACE) inhibitors or angiotensin receptor (AT) antago-
nists, ameliorates renal damage and decreases protein-
uria [1–3]. Many studies have investigated the molecular
mechanisms involved in AngII-induced renal damage. In
cultured renal cells, AngII causes hypertrophy or pro-
liferation, depending on the cell type, overexpression of
proinflammatory factors, and accumulation of extracel-
lular matrix proteins [1, 2, 4]. Systemic infusion of AngII
causes renal damage [5–9] through the activation of in-
tracellular signaling systems and the regulation of several
mediators. We have observed that AngII increases renal
activity of the nuclear factor-jB (NF-jB) and upregu-
lates NF-jB-related cytokines and chemokines, including
tumor necrosis factor-a (TNF-a) and monocytic chemo-
tactic protein-1 (MCP-1), correlated with the presence
of inflammatory cells [7, 8]. In addition, in AngII-infused
rats, overexpression of profibrotic factors, such as the con-
nective tissue growth factor (CTGF), was observed in the
kidney and in the aorta in association with extracellular
matrix accumulation [9, 10].
AngII acts through two receptor subtypes, AT1 and
AT2. The AT1 are G-coupled receptors and activate small
G proteins, including Ras, Rac1, RhoA, and the Rho-
kinase system [11, 12]. Recently, the Rho family of small
guanosine triphosphatase (GTPase) has been reported
as playing an important role in AngII signaling, including
actin reorganization, vasoconstriction, hypertrophy, and
gene expression [12–15]. The Rho family of GTP-binding
proteins, which includes Rho, Rac, and Cdc42, among 30
proteins, has well-documented effects on cellular contrac-
tion, proliferation, actin cytoskeletal organization, and
regulation of gene transcription [16]. Rho GTPases act as
molecular switches driving upstream signals to a plethora
of downstream effector pathways. Several studies suggest
that Rho-kinase, a downstream effector molecule of Rho
[17], plays an important role for various cellular func-
tions, including focal adhesions, motility, contraction, and
cytokinesis [18–21]. In hypertensive rats, the Rho-kinase
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system in blood vessels is activated and contributes to
the pathogenesis of hypertensive vascular disease [22].
Rho has recently been implicated in the etiology of re-
nal fibrosis, and it seems to be necessary for transform-
ing growth factor b (TGF-b)-induced upregulation of
CTGF [23]. The Rho-kinase inhibitor Y-27632 reduces
tubulointerstitial fibrosis in a mouse model of unilateral
ureteral obstruction [24]. Thus, Rho signaling pathways
could be regarded as a novel therapeutic target for hyper-
tension and renal damage. Strategies designed to target
this molecule have been successful in animal models, and
some are currently in clinical trials [25].
Our aim was to investigate whether the Rho/Rho-
kinase pathway could modulate some in vivo AngII re-
sponses in the kidney. For these studies, we evaluated the
effect of the Rho-kinase inhibitor Y-27632, a selective in-
hibitor of the serine/threonine Rho-kinases I and II that
is competitive for their adenosine triphosphate-binding
site [26, 27], in renal damage caused by systemic infu-
sion of AngII, and studied the effect on the regulation of
proinflammatory and profibrotic factors.
METHODS
Materials
The selective inhibitor of Rho-associated kinase Y-
27632 was from TOCRIS Cookson (Bristol, UK). Rabbit
anti-CTGF antibody was obtained from Torrey Pines Bi-
olabs (Houston, TX, USA) [9], anti-tubulin from Sigma
(St. Louis, MO, USA), and secondary antibodies from
Amersham Biosciences (Piscataway, NJ, USA).
Experimental studies
AngII was systemically infused into female Wistar
rats (subcutaneously by osmotic minipumps, Alza Corp.,
Mountain View, CA, USA), at a dose of 100 ng/kg per
minute. To determine the effect of Rho-kinase activa-
tion, a group of rats was treated daily with the Rho-kinase
inhibitor Y-27632 (30 mg/kg per day, intraperitoneally),
starting 24 hours before AngII-infusion. Animals were
sacrificed at three days (N = 7 rats each group). The
kidneys were immediately removed, a part was frozen
for RNA and protein studies, and the rest was fixed
and paraffin-embedded [9]. Control groups of animals
infused with saline solution with or without treatments
were also studied. Animals were handled following Eu-
ropean guidelines.
Gene and protein studies
Total RNA was isolated with Trizol (Gibco, Rockville,
MD, USA), and gene expression was analyzed by
reverse-transcriptase polymerase chain reaction [8].
The specific primers used were: TNFa (sense: 5′-
ATGAGCACAGAAAGCATGATCC -3′, antisense:
5′-GAAGATGATCTGAGTGTG -3′), MCP-1 (sense:
5′-TTCTGGGCCTGTTGTTCACA-3′, antisense: 5′-
GGTCACTTCTACAGAAGTCC-3′) [28], and G3PDH
(sense: 5′-AATGCATCCTGCACCACCAA-3′, anti-
sense: 5′-GTAGCCATATTCATTGTCATA-3′), which
yield a 251 bp, 409 bp, and 515 bp product, and poly-
merase chain reaction (PCR) (1 minute at 94◦C, 1 minute
at 60◦C/58◦C/54◦C, and 1 minute at 68◦C; 32/25/25 cycles,
respectively).
The kidney samples were studied by staining with
hematoxylin and eosin and Masson’s stain, and exam-
ined by light microscopy. CTGF expression as evalu-
ated by immunohistochemistry. Paraffin-embedded renal
tissue sections (4 lm) were deparaffinized and rehy-
drated, and endogenous peroxidase was blocked by in-
cubating in 3% H2O2/methanol (1:1) at 25◦C for 30
minutes. The slides were subsequently incubated in
phosphate-buffered saline (PBS) solution with 6% serum
in 4% bovine serum albumin (BSA) for 1 hour at
37◦C to reduce nonspecific background staining, and
then incubated overnight at 4◦C with primary anti-
body in PBS containing 1% serum and 4% BSA.
After being washed with PBS, the sections were in-
cubated with secondary antibody diluted 1:200 in 4%
BSA/PBS for 30 minutes and, after washing, they were
revealed by standard techniques. Evaluations were per-
formed by two independent observers in a blinded fash-
ion, and the mean score value was calculated for each rat.
Negative controls without the primary antibody, or using
an unrelated immunoglobulin G, were included to check
for nonspecific staining (not shown).
For western blotting, tissue was homogenized in lysis
buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 2 mmol/L
ethylenediamine tetraacetic acid, 2 mmol/L EGTA, 0.2%
Triton X-100, 0.3% NP-40, 0.1 mmol/L phenyl methyl
sulphonyl fluoride, and 1 lg/mL pepstatin A) and then
separated by 12% sodium dodecylsulfate-polyacrylamide
gel electrophoresis under reducing conditions. After elec-
trophoresis, samples were transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, MA, USA).
The membranes were blocked in PBS containing 0.1%
Tween-20 and 5% dry skimmed milk for 1 hour at 37◦C,
and then incubated in the same buffer with specific CTGF
antibody for 18 hours at 4◦C. After washing, detec-
tion was made by incubation with peroxidase-conjugated
secondary antibody, and developed using an enhanced
chemiluminescence kit (Amersham). In all experiments,
protein content was determined with the bicinchoninic
acid method. In addition, Ponceau Red staining was used
to show quality of proteins and the efficacy of protein
transfer to the membrane (not shown), and tubulin was
used as a loading control.
The autoradiographs were scanned with the GS-
800 Calibrated Densitometer (Quantity One; BioRad,
Madrid, Spain), which obtained densitometric arbi-
trary units. Data were normalized against those of the
corresponding G3PDH or tubulin data. Results are
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Fig. 1. The Rho-kinase inhibitor Y-27632
ameliorates renal damage caused by systemic
infusion of AngII. Animals were treated daily
with Y-27632 (30 mg/kg per day), starting
24 hours before AngII infusion (100 ng/kg
per minute) and studied after three days. (A)
The figure shows representative photomicro-
graphs of the kidney from one animal of each
group. Magnification 100×. (B) The semi-
quantitative score as mean ± SEM of seven
animals of each group. ∗P < 0.05 vs. control.
#P < 0.05 vs. AngII. Control animals showed
no renal damage. Black bars represent AngII-
infused rats and white bars rats treated with
Y-27632.
expressed as n-fold increase over control in densitomet-
ric arbitrary units, and as mean ± standard error of the
mean (SEM) of the experiments undertaken.
Statistical analysis
Significance was established with GraphPAD Instat us-
ing Student’s t test and analysis of variance (GraphPAD
Software, San Diego, CA, USA). Differences were con-
sidered significant at a value of P < 0.05.
RESULTS
Rho-kinase inhibition diminishes renal damage caused
by systemic infusion of AngII
Morphologic lesions were examined by light mi-
croscopy. After three days of AngII infusion, animals
presented inflammatory cells in glomeruli and in tubu-
lointerstitial areas, mild tubular lesions (Fig. 1), but not
fibrosis, as previously described [7]. Treatment with the
Rho-kinase inhibitor Y-27632 ameliorates renal damage
(Fig. 1).
Rho-kinase inhibition diminishes renal overexpression of
proinflammatory mediators caused by systemic infusion
of AngII
In rats infused with AngII for three days, NF-jB activ-
ity was elevated in the kidney. Treatment with Y-27632
partially diminished renal NF-jB DNA binding activity
in AngII-infused rats (around 60% inhibition vs. AngII-
infusion; electrophoretic mobility shift assay [EMSA],
Control Angll
Angll
+ Y-27632
Fig. 2. Rho-kinase inhibition decreased NF-jB activation caused by
AngII. Protein extracts were collected and used for gel shift assays with
the NF-jB probe. The figure shows a representative EMSA experiment
of seven animals of each group. Specificity of the reaction was demon-
strated with a 100-fold excess of unlabelled NF-jB oligonucleotide (not
shown).
Fig. 2). We evaluated by PCR the gene expression of
proinflammatory mediators, such as the cytokine TNF-a
and the chemokine MCP-1. AngII-infused rats presented
overexpression of these proinflammatory genes that were
downregulated by Y-27632 (Fig. 3).
Rho-kinase inhibition diminishes renal CTGF
upregulation caused by systemic infusion of AngII
The CTGF gene was upregulated in the kidneys of
AngII-infused rats, and CTGF protein production was
increased in glomeruli, some tubuli, and renal vessels.
Treatment of AngII-infused animals with the Rho-kinase
inhibitor Y-27632 diminished CTGF messenger RNA and
protein production (immunohistochemistry and Western
blot) in all renal structures (Fig. 4).
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Fig. 3. Rho-kinase inhibition downregulated
AngII-induced renal overexpression of proin-
flammatory mediators. Total cortex RNA was
extracted, and gene expression of proinflam-
matory mediators (TNFa and MCP-1) was an-
alyzed by PCR. Panel A shows a representa-
tive experiment, and panel B shows data as
mean ± SEM of seven animals of each group.
G3PDH gene expression was used as a con-
trol. ∗P < 0.05 vs. control; #P < 0.05 vs. AngII.
DISCUSSION
We observed that treatment with the Rho-kinase
inhibitor Y-27632 ameliorates AngII-induced renal
damage, diminishing the presence of inflammatory cell
infiltration and tubular lesions, as well as the overex-
pression of proinflammatory and profibrotic mediators.
These data suggest the in vivo role of Rho activation
in AngII responses. Rho family GTPases are key com-
ponents of signaling pathways that regulate several cel-
lular functions and processes, such as vasoconstriction,
actin reorganization, leukocyte transmigration, and cell
growth [16]. RhoA participates in some AngII responses,
including vasoconstriction, premyofibril formation, and
hypertrophy of cardiomyocytes and vascular smooth
muscle cell (VSMC) [11, 12, 15]. Rho-kinase is one of the
target proteins of RhoA. In VSMC, Rho-kinase inhibi-
tion significantly suppressed AngII-induced hypertrophic
response and downregulated AngII-induced genes, in-
cluding MCP-1 and plasminogen-activator inhibitor-1
[11–15]. In this sense, we have observed that in AngII-
infused rats, Rho-kinase inhibition diminished gene over-
expression of MCP-1, TNFa, and CTGF. Our data clearly
indicate that the Rho/Rho-kinase pathway participates
in AngII-mediated renal damage and suggest that treat-
ments that block Rho/Rho-kinase activation could be
very useful in pathologic settings associated with elevated
local AngII generation. At the doses used, the effects of
Y-27632 on AngII-induced renal damage are shown to be
responsible for specific inhibition of Rho-kinase, whereas
the inhibition of other kinases, such as citron kinase and
protein kinase N (PKN), is rarely observed using Y-27632
[26, 27]. Nevertheless, a small in vivo contribution of other
Rho effector kinases, besides Rho-associated kinase, can-
not be ruled out.
The recruitment of inflammatory cells plays a key role
in the onset and progression to irreversible structural re-
nal changes. AngII is a cytokine that participates in the
inflammatory response. AngII activates the endothelium
and causes the adhesion of monocytes and neutrophils
to endothelial, VSMC, and mesangial cells, through the
upregulation of adhesion molecules, such as P- and E-
selectin, intercellular adhesion molecule-1, and vascu-
lar cell adhesion molecule-1 [1]. AngII stimulation of
resident renal cells produces cytokines and chemokines,
which contributes to the recruitment of infiltrating cells
into the kidney, such as MCP-1, the main chemokine
of monocytes [1]. The NF-jB pathway plays a key role
in the progression of kidney damage. This transcrip-
tion factor regulates many genes that are vital in the
inflammatory process [29]. AngII activates the NF-jB
pathway, although depending on the cell type, different
AngII receptors are involved [1, 4]. Rho proteins par-
ticipate in NF-jB activation [30]. We found that Rho-
kinase inhibition partially diminished NF-jB activation.
We have previously demonstrated that both AT1 and
AT2 receptors are involved in renal NF-jB activation.
In particular, the inhibitory effect observed with the AT1
antagonists was similar to that found with the Rho-kinase
inhibitor, supporting the idea that, through activation of
AT1 and Rho, AngII regulates the NF-jB pathway in
the kidney. AngII increases proinflammatory genes under
NF-jB control, including adhesion molecules, cytokines,
and chemokines. In unilateral ureteral obstruction and
nephrectomized spontaneously hypertensive rats, fasudil,
another Rho-kinase inhibitor, diminished ED-1-positive
cell infiltration [31, 32]. We have demonstrated that Rho-
kinase inhibition diminished AngII-induced renal inflam-
matory response, as shown by lower renal inflammatory
cell infiltration, diminution of NF-jB activity, and down-
regulation of proinflammatory genes, including the cy-
tokine TNF-a and the chemokine MCP-1. These data
show that Rho-kinase inhibition regulates the inflamma-
tory response in the kidney.
Several findings suggest a potential role of the
Rho/Rho-kinase signaling pathway in the development
of fibrotic lesions in various organs, including the kid-
ney. Tubulointerstitial fibrosis is a final common path-
way to end-organ damage, and therefore is an important
therapeutic target to cure or reverse progressive func-
tional deterioration. In different experimental models of
renal damage, such as hypertensive glomerulosclerosis,
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Fig. 4. The Rho-kinase inhibitor Y-27632 diminished CTGF overexpression in the kidney of AngII-infused rats. (A) CTGF gene expression
determined by reverse-transcriptase polymerase chain reaction. CTGF protein levels were evaluated by immunohistochemistry (B) and Western
blot (C). In A and C, the left panel shows a representative experiment, and the right panel shows the data as mean ± SEM of 7 animals of each
group. ∗P < 0.05 vs. control, #P < 0.05 vs. AngII. B shows representative animals of 7 studied in each group. Magnification in B 400×.
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unilateral ureteral obstruction, nephrectomized sponta-
neously hypertensive rats, and in rats treated with L-
NAME, Rho-kinase inhibition improved glomerular and
tubulointerstitial injury scores and fibrosis [24, 31–35].
In nephrectomized spontaneously hypertensive rats, the
Rho-kinase inhibitor fasudil ameliorated proliferating
cell nuclear antigen-positive cells, through upregulation
of p27kip1, a cyclin-dependent kinase inhibitor [31]. In
some of these models, Rho-kinase inhibition diminished
gene overexpression of smooth muscle a-actin, TGF-b ,
and extracellular matrix proteins [24, 34]. In rats infused
with AngII, we show that Y-27632 diminished tubular
damage and overexpression of the profibrotic growth fac-
tor CTGF. This growth factor is upregulated in many hu-
man renal diseases and contributes to renal fibrosis and
tubuloepithelial transdifferentiation [36, 37]. In cultured
renal fibroblasts, activation of Rho is involved in TGF-b-
induced CTGF overexpression [23] but not in fibroblasts
proliferation [24]. Although drugs that block renal AngII
production, such as ACE inhibitors and AT1 antagonists,
have demonstrated protective renal effects and can ame-
liorate fibrosis through CTGF downregulation [10], the
data presented here suggest that Rho-kinase inhibitors
could be novel targets for renal therapy.
The Rho/Rho-kinase pathway also plays a crucial role
in blood pressure regulation in vivo [38]. In different mod-
els of hypertension, activation of RhoA has recently been
described [39], suggesting that the Rho/Rho-kinase path-
way could be a potential mechanism that explains vascu-
lar changes in hypertension.
Although different treatments present beneficial ef-
fects in renal diseases, novel targets for renal therapy
are needed to improve the quality of life of these pa-
tients. Many therapeutic treatments currently used, such
as ACE inhibitors and 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors, present pleiotropic effects
and target pivotal cell-signaling networks besides the
pathways they were initially designed to regulate. In this
sense, 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors block activation of Rho, showing an in-
tracellular target of their beneficial effects. Our results
suggest that renal damage induced by AngII is mediated
by activation of the Rho/Rho-kinase pathway, and sup-
port the idea that treatments that inhibit this pathway
could be an appropriate choice for therapeutic strategies
in renal diseases.
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